It is a leading cause of hospitalization and a growing and costly burden on the health system.

Heart failure is a disease that afflicts more than 5 million Americans and an estimated 15 million patients worldwide. It is a leading cause of hospitalization and a growing and costly burden on the health system. It is estimated that the U.S. Healthcare system is a projected spend $ 28800000000 for the care of patients with heart failure in 2005.

Connected While this study examined the SP4 protein levels, mutations in the gene encoding the SP4 protein with psychiatric disorders, including bipolar disorder, a poorly understood disease characterized by episodes of abnormally elevated energy levels with or without depressive episodes and schizophrenia in been and depressive disorder. Thus, our study on the growing body of evidence adds that changes in gene regulation contribute to the development of mental illness, said Ramos.. Ramos explained Thus, our of proteins such as transcription factors known to regulate gene expression.In addition, the company will continue risk for human or animal test, in producing ABthrax and FDA approval of that ABthrax contract satisfies the demands of the ABthrax the face. In If the Company will not in a position to.. Safe Harbor StatementThis communication contains forward looking statements the purposes of section 27A of the Securities Act of 1933, as amended and Section 21E under the Securities Exchange Act of 1934 as amended. The forward-looking information is based on Human Genome Sciences are based current intent, belief and expectation. Such statements contain no guarantees of future performance and involve certain risks and uncertainties which difficult to predict.

ABthrax be in late-stage development for the treatment of inhalation anthrax, and the company is is on their way order delivering to begin in autumn, 2008 of 20,000 doses of ABthrax of the Strategic National the Stockpile below a contract concluded into the U.S. Government in June 2006. Other medicaments under clinical development comprise HGS two TRAIL receptor antibodies and small molecule of antagonists of the IAP proteins for the treatment of cancer. In addition, HGS has serious financial rights to three product in which Glaxo Smith Kline clinical development pipeline.